



International Technology Transfers: A Playbook for Success Priscilla Pingrey, Teresa Henry, Liza Lamb, Lyndsey Brumbach, Karim Dudum Syner-G Biopharma Group | Sequoia Biotech Consulting San Diego, CA

BACKGROUND

The BIOSECURE Act and the push for reshoring manufacturing to the US are **Technology Transfer Playbook** driving complexities in pharmaceutical manufacturing. International technology Our technology transfer playbook facilitates a smooth transition of knowledge, transfers require effective coordination among cross-functional teams and become more complex across global sites due to evolving regulations and operational constraints, increasing the risk of misalignment and inefficiencies that can negatively affect time to market, product quality, and patient outcomes. To address these issues, Syner-G | Sequoia have developed a technology transfer playbook offering a strategic framework for effective planning and execution. alignment and support from stakeholders throughout the project's progression. Supported by proven case studies, this approach turns challenges into opportunities for effective implementation, improving outcomes for both organizations and patients.

METHODS





Figure 1. Critical Tech Transfer Milestones Across the Product Development Lifecycle

developed to ensure a seamless transition. Technology transfers occur at different scale-up inflection points throughout the product lifecycle, each characterized by distinct drivers, requirements, and **Readiness:** Involves ensuring that the receiving site is fully prepared for success criteria. As a product advances from preclinical to clinical phases and execution of production runs. Punch list items from Knowledge Transfer are ultimately to commercialization, it is critical to employ a technology transfer addressed, and equipment qualification, method validation, and regulatory framework that focuses on the effective transfer of product specifications and compliance activities are finalized. process knowledge, along with ensuring regulatory compliance.

Phase	Key Drivers	Technology Transfer & Regulatory Focus	Technical Considerations
Preclinical Development	Establishing proof of concept Preparing for IND/CTA submission Early process feasibility	 Establish process Document critical product specifications Preparation for regulatory submission 	 Small-scale, non-GMP production Initial analytical assay development Process scalability and reproducibility testing
Early Phase •	First-in-human (FIH) trials Demonstrating safety Ensuring regulatory compliance (GMP readiness)	 Process knowledge transfer R&D to GMP manufacturing Process refinement for clinical production Approval requirements for clinical trials 	 Transitioning to GMP manufacturing Analytical method and process qualification. Scaling processes for later-stage trials Supply chain and raw material qualification
	Pivotal trials for efficacy confirmation Scaling up for broader patient access Preparing for commercial launch	 Technology transfer to commercial- scale manufacturing Process validation and regulatory submission readiness (BLA/NDA/MAA) Establishing robust supply chain 	 Process validation, optimization, and comparability studies Analytical method validation Site selection and qualification for large-scale production
Commercial / Post-Market Surveillance	Routine, large-scale production Consistency and cost efficiency Post-market regulatory commitments	 Lifecycle technology transfer to ensure ongoing process improvements Continued process verification (CPV and regulatory compliance Post-marketing surveillance and risk management 	 Long-term supply chain strategy

 Table 1. Technology Transfer Considerations Across Product Development Stages



program management ensures coordination across cross-functional teams and effective risk management to maximize program efficiency.

Knowledge Transfer: Document handover, structured training and workshops, and gap identification/mitigation planning. A final punch list of site-specific modifications, quality system adaptations, and workflow harmonization is

Execution: Focuses on product performance, ensuring phase appropriate validation. Pilot runs identify and resolve production challenges, enabling process refinement before formal validation.

Handover: Official transfer of the process ownership to the receiving unit. All documentation, including tech transfer reports, batch records, and validation summaries are in a final state.

CASE STUDY

A world leading supplier faced a serious challenge during critical vaccine development: they needed to rapidly scale up the production capacity of their animal-origin-free enzymes to meet the growing demand for raw materials. This initiative would require the construction and validation of two new US-based manufacturing sites and the international technology transfer of their manufacturing processes. Given the magnitude of scope and need for specialized expertise, this leading supplier partnered with Syner-G | Sequoia to successfully scope, staff, and execute the tech transfer.

Figure 3. Engineering V-Model

We assembled a specialized team of quality, engineering, and project management experts to create a cross-functional core team and governance structure for defining project objectives, scope, and success criteria. During the planning phase, we identified CQAs and CPPs and developed a compliant tech transfer roadmap while designing new facilities aligned with these objectives. Our team collaborated closely with the client to develop tailored strategies utilizing the Engineering V-Model for manufacturing scale-up. In knowledge transfer, we refined facility designs, revised quality documents to meet North American standards, developed a phase-appropriate QMS, authored SOPs, and planned for CQV. Once the facility was constructed and operational infrastructure established, we implemented a PM program and successfully completed CQV. During execution, we performed engineering runs to establish process confidence, followed by PPQs to ensure reliable production. After the successful startup, we ensured the client could manage ongoing operations by addressing outstanding items, preparing final reports, conducting training, and resolving deviations and CAPAs.

CONCLUSION

While technology transfers are inherently complex and further complicated by changing regulatory environments and operational constraints, fostering consensus and collaboration within a strong cross-functional team can effectively minimize disruptions and ensure compliance. By forming the right partnerships and utilizing proven strategies, organizations can transform the challenges of technology transfer into opportunities for efficient execution and successful implementation, ultimately leading to better outcomes for both organizations and patients.

Applying the Tech Transfer Playbook